Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes.
View Top Employees from Capstone TherapeuticsWebsite | http://www.capstonethx.com |
Ticker | CAPS |
Revenue | $2 million |
Employees | 9 (9 on RocketReach) |
Founded | 2008 |
Address | 1275 W Washington St Ste 104, Tempe, Arizona 85281, US |
Phone | (602) 286-5520 |
Technologies |
JavaScript,
HTML,
PHP
+4 more
(view full list)
|
Industry | Biotechnology, Manufacturing General, Manufacturing, Science and Engineering, Pharmaceuticals, Health Care |
Web Rank | 13 Million |
Keywords | Capstone Therapeutics, Capstone Therapeutics Corp |
Competitors | Biorthex Inc., Curemark, LLC, MedShape, Inc., Nobex Corporation, Novastep USA |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 325414 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 541711 Companies, NAICS Code 541 Companies |
Looking for a particular Capstone Therapeutics employee's phone or email?
The Capstone Therapeutics annual revenue was $2 million in 2024.
Jock Holliman is the Executive Chairman and Principal Executive Officer of Capstone Therapeutics.
9 people are employed at Capstone Therapeutics.
Capstone Therapeutics is based in Tempe, Arizona.
The NAICS codes for Capstone Therapeutics are [325, 3254, 325414, 54, 5417, 54171, 32, 32541, 541711, 541].
The SIC codes for Capstone Therapeutics are [283, 28].